Comparative Pharmacology
Head-to-head clinical analysis: TECHNESCAN HDP versus TECHNETIUM TC 99M MEBROFENIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TECHNESCAN HDP versus TECHNETIUM TC 99M MEBROFENIN.
TECHNESCAN HDP vs TECHNETIUM TC-99M MEBROFENIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Technetium Tc-99m oxidronate (HDP) is a bone-seeking radiopharmaceutical that localizes to areas of osteoblastic activity. It binds to hydroxyapatite crystals in bone via chemisorption, allowing scintigraphic imaging of skeletal lesions.
Technetium Tc-99m mebrofenin is a radiopharmaceutical that, after intravenous administration, is taken up by hepatocytes and excreted into the biliary system. It allows scintigraphic imaging of the liver and biliary tract by emitting gamma rays detectable by a gamma camera.
For bone scintigraphy: 740 MBq (20 mCi) intravenous injection.
Adults: 1-5 mCi (37-185 MBq) IV bolus. Image immediately and at intervals up to 60 minutes for hepatobiliary scintigraphy.
None Documented
None Documented
Clinical Note
moderateTechnetium Tc-99m mebrofenin + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Technetium Tc-99m mebrofenin."
Clinical Note
moderateTechnetium Tc-99m mebrofenin + Eltrombopag
"The serum concentration of Eltrombopag can be increased when it is combined with Technetium Tc-99m mebrofenin."
Terminal elimination half-life is approximately 2-3 hours for the diphosphonate component, with clinical imaging typically performed 2-4 hours post-injection.
Terminal elimination half-life: approximately 6 hours (range 4-8 hours) in patients with normal hepatic function. In obstructive jaundice, half-life may be prolonged due to delayed biliary excretion.
Renal: >95% excreted unchanged in urine within 24 hours. Biliary/fecal: <5%.
Primarily biliary (hepatobiliary) excretion: ~75% of administered activity is excreted into bile and subsequently into feces within 24 hours. Renal excretion accounts for <10% of the administered dose.
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical